These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36437796)

  • 1. Computational screening of natural products to identify potential inhibitors for human neuropilin-1 (NRP1) receptor to abrogate the binding of SARS-CoV-2 and host cell.
    Karkashan A; Attar R
    J Biomol Struct Dyn; 2023 Nov; 41(19):9987-9996. PubMed ID: 36437796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of natural products to block SARS-CoV-2 S-protein interaction with Neuropilin-1 receptor: A molecular dynamics simulation approach.
    Alshawaf E; Hammad MM; Marafie SK; Ali H; Al-Mulla F; Abubaker J; Mohammad A
    Microb Pathog; 2022 Sep; 170():105701. PubMed ID: 35963279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abrogation of SARS-CoV-2 interaction with host (NRP1) neuropilin-1 receptor through high-affinity marine natural compounds to curtail the infectivity: A structural-dynamics data.
    Humayun F; Khan A; Ahmad S; Yuchen W; Wei G; Nizam-Uddin N; Hussain Z; Khan W; Zaman N; Rizwan M; Waseem M; Wei DQ
    Comput Biol Med; 2022 Feb; 141():104714. PubMed ID: 34772509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the mechanism of interaction of SARS-CoV-2 B.1.640.2 variant RBD with the host receptors hACE2 and GRP78.
    Shafiq A; Khalid U; Abdur Rehman U; Abdullah Almuqri E; Muddassir M; Ahmad S; Khan MI; Khan A; Wei DQ
    J Biomol Struct Dyn; 2024; 42(4):2034-2042. PubMed ID: 37286365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition potential of natural flavonoids against selected omicron (B.1.19) mutations in the spike receptor binding domain of SARS-CoV-2: a molecular modeling approach.
    Kumar A; Dutt M; Dehury B; Sganzerla Martinez G; Swan CL; Kelvin AA; Richardson CD; Kelvin DJ
    J Biomol Struct Dyn; 2023 Dec; ():1-15. PubMed ID: 38115191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapeutic Potential of Natural Products to Target the SARS-CoV-2 PLpro Using Molecular Screening and Simulation Approaches.
    Sayaf AM; Ahmad H; Aslam MA; Ghani SA; Bano S; Yousafi Q; Suleman M; Khan A; Yeoh KK; Wei DQ
    Appl Biochem Biotechnol; 2023 Nov; 195(11):6959-6978. PubMed ID: 36961512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the RBD of Omicron Variant (B.1.1.529) with Medicinal Phytocompounds to Abrogate the Binding of Spike Glycoprotein with the hACE2 Using Computational Molecular Search and Simulation Approach.
    Hakami AR
    Biology (Basel); 2022 Feb; 11(2):. PubMed ID: 35205124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of SARS-CoV-2 ORF6-KPNA2 binding interface and identification of potent small molecule inhibitors to recuse the host immune system.
    Suleman M; Said A; Khan H; Rehman SU; Alshammari A; Crovella S; Yassine HM
    Front Immunol; 2023; 14():1266776. PubMed ID: 38283360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of dual S-RBD/NRP1-targeting peptides: structure-based virtual screening, synthesis, biological evaluation, and molecular dynamics simulation studies.
    Hu C; Guo T; Zou Y; Gao J; Gao Y; Niu M; Xia Y; Shen X; Li J
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2212327. PubMed ID: 37194732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultra-Large-Scale Screening of Natural Compounds and Free Energy Calculations Revealed Potential Inhibitors for the Receptor-Binding Domain (RBD) of SARS-CoV-2.
    Guo L; Zafar F; Moeen N; Alshabrmi FM; Lin J; Ali SS; Munir M; Khan A; Wei D
    Molecules; 2022 Oct; 27(21):. PubMed ID: 36364143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction analysis of SARS-CoV-2 omicron BA1 and BA2 of RBD with fifty monoclonal antibodies: Molecular dynamics approach.
    Sandhya KS; Kishore AA; Unni A; Sunitha P; Sajithra CV; Nair AS
    J Mol Graph Model; 2024 May; 128():108719. PubMed ID: 38324968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neohesperidin and spike RBD interaction in omicron and its sub-variants: In silico, structural and simulation studies.
    Singh JK; Dubey S; Srivastava G; Siddiqi MI; Srivastava SK
    Comput Biol Med; 2023 Jan; 152():106392. PubMed ID: 36502697
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of bioactive molecule from
    Tripathi MK; Singh P; Sharma S; Singh TP; Ethayathulla AS; Kaur P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5668-5681. PubMed ID: 32643552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 25 (S)-Hydroxycholesterol acts as a possible dual enzymatic inhibitor of SARS-CoV-2 M
    Alzahrani FA; Alkarim SA; Hawsawi YM; Abdulaal WH; Albiheyri R; Kurdi B; Alguridi H; El-Magd MA
    J Biomol Struct Dyn; 2023 Jul; 41(10):4744-4755. PubMed ID: 35510619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the binding and dynamic features of A.30 variant revealed higher binding of RBD for hACE2 and escapes the neutralizing antibody: A molecular simulation approach.
    Shafiq A; Zubair F; Ambreen A; Suleman M; Yousafi Q; Rasul Niazi Z; Anwar Z; Khan A; Mohammad A; Wei DQ
    Comput Biol Med; 2022 Jul; 146():105574. PubMed ID: 35533461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
    Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urtica dioica agglutinin (UDA) as a potential candidate for inhibition of SARS-CoV-2 Omicron variants: In silico prediction and experimental validation.
    Sabzian-Molaei F; Hosseini S; Alipour A; Ghaderi H; Fotouhi-Chahouki F; Hadi A; Shahsavarani H
    Phytomedicine; 2023 Mar; 111():154648. PubMed ID: 36681052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.